I

Indiana Hemophilia and Thrombosis Center | Indianapolis, IN

Research site

(Unclaimed)

Location

8326 Naab Road, Indianapolis, Indiana, United States of America

Site insights

Top conditions

Top treatments

Edoxaban

Efanesoctocog Alfa

Metformin

Voxelotor

AG-348

Pyruvate

DDAVP

Emicizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 30 total trials

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (no...

Enrolling

Von Willebrand Disease (VWD)

Biological: rVWF

Biological: rFVIII

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

The main aim of the study is to check effectiveness, side effects, and tolerability of recombinant von Willebrand Factor (rVWF), with or without ADVA...

Enrolling

Von Willebrand Disease

Biological: Antihemophilic Factor (Recombinant)

Biological: von Willebrand factor (Recombinant)

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2)

This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hem...

Active, not recruiting

Hemophilia B

Biological: PF-06838435/ fidanacogene elaparvovec

Emicizumab in Patients With Acquired Hemophilia A (AHAEmi)

This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a schedul...

Enrolling

Acquired Hemophilia A

Drug: emicizumab